Medi Assist to increase stake in Mayfair We Care to 91.75% for INR equivalent of GBP 589,270

What Medi Assist announced

Medi Assist Healthcare Services Limited disclosed that its Board, on 24 June 2026, approved a further cash investment to acquire an additional 31.75 % of Mayfair We Care Limited, a UK‑based subsidiary. The purchase will raise Medi Assist’s shareholding in Mayfair from 60 % to 91.75 % of the issued share capital. The acquisition will be executed through a share transfer from existing shareholders and is funded entirely by cash.

"The Board has approved a further investment of INR equivalent to GBP 589,270 for the additional acquisition of 31.75 % shares of Mayfair We Care Limited."

Details of the acquisition

The transaction involves the purchase of 1,270 ordinary shares, representing 31.75 % of Mayfair’s issued share capital. The consideration is cash, amounting to INR equivalent to GBP 589,270 as of the remittance date. Funding will come from the proceeds of a preferential allotment previously raised for general corporate purposes; no new share issuance is required, thus avoiding dilution of existing shareholders.

Mayfair’s financial snapshot for the fiscal year ended 31 Mar 2026 shows a turnover of INR 410.85 million and a net profit after tax of INR 16.31 million. The company operates in the insurance intermediary sector, providing health‑claim and health‑benefits administration services to the global health‑insurance market.

The acquisition is expected to close by the end of the second quarter of FY 2026‑27, subject to customary closing formalities. No governmental or regulatory approvals are required beyond standard corporate clearances, as the transaction is between the listed company and its existing subsidiary and is being conducted on an arm‑length basis.

Management changes at Mayfair

Alongside the share purchase, Medi Assist announced leadership restructuring at Mayfair. Mr. Nikhil Chopra, currently Chief Business Officer of Medi Assist and a Director of Mayfair, will be appointed CEO‑designate of Mayfair. Upon completion of the acquisition, he will assume the role of CEO, subject to receipt of all requisite approvals.

Concurrently, Mr. Michail Chopra, the incumbent CEO of Mayfair, will transition to the role of Founder & Strategic Advisor. Both appointments will become effective once all formalities relating to the transaction are satisfied.

Key facts at a glance

Why this matters for investors

The acquisition deepens Medi Assist’s control over Mayfair, moving from a majority stake to near‑total ownership. This consolidation can enable more streamlined decision‑making, potential cost synergies, and stronger alignment with Medi Assist’s cross‑border health‑administration strategy. Because the purchase is funded with cash from an earlier preferential allotment, there is no immediate dilution of existing shareholders’ equity.

However, the cash outflow of roughly INR 5 crore (GBP 589,270) reduces the company’s liquid resources. Investors should monitor the utilisation of these funds and the integration progress of Mayfair’s operations. The leadership change signals a tighter operational grip, with the board placing a senior executive (Nikhil Chopra) at the helm of the subsidiary.

Conclusion

Medi Assist’s board has approved a cash acquisition that will increase its holding in Mayfair We Care to 91.75 %, accompanied by a change in Mayfair’s top management. The deal is slated to close by the end of Q2 FY 2026‑27 and is financed from existing preferential allotment proceeds, meaning no new shares will be issued. Completion will give Medi Assist near‑full control of a subsidiary with a modest turnover and profit, positioning it to pursue its international health‑administration ambitions.

---

FAQs

Q: What is the total consideration for the additional Mayfair shares? A: The cash consideration is INR equivalent to GBP 589,270, as stated in the board resolution dated 24 June 2026.

Q: How will the acquisition be funded? A: Funding will come from the proceeds of a preferential allotment that were earmarked for general corporate purposes; no new equity is being issued.

Q: When is the transaction expected to close? A: The acquisition is expected to close by the end of the second quarter of FY 2026‑27, subject to customary closing formalities.

Q: What are Mayfair’s recent financial results? A: For the year ended 31 Mar 2026, Mayfair reported a turnover of INR 410.85 million and a net profit after tax of INR 16.31 million.

Q: Who will lead Mayfair after the deal? A: Mr. Nikhil Chopra will become CEO‑designate and will assume the CEO role upon completion; Mr. Michail Chopra will become Founder & Strategic Advisor.

Q: Does the transaction require any regulatory approvals? A: The filing states that no governmental or regulatory approvals are applicable beyond standard corporate clearances.